Clinical Trial

Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Name: Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07510100)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FUMANBA-04

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.

Trial Details

NCT Number	NCT07510100
Lead Sponsor	Nanjing IASO Biotechnology Co., Ltd.
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	17 participants
Start Date	2026-05-10
Primary Completion	2029-08-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-03